Sandoz (ADR)

BOUCHERVILLE, Quebec, March 18, 2025 (GLOBE NEWSWIRE) -- Sandoz Canada, the leader in generic and biosimilar medicines in Canada, has signed a 10-year, long-term supply agreement with its partner Delpharm, a global pharmaceutical developer and contract manufacturer. This partnership, along with financial backing from the Government of Canada, will allow Delpharm to carry out its modernization plan for its Boucherville plant.» Mehr auf globenewswire.com

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE FY 2024 net sales[1] of USD 10.4 billion, up by 9%[2] in constant currencies (+7% in USD); Q4 net sales of USD 2.7 billion, up by 9% in constant currencies (+7% in USD) Strong sales performances in all three regions, driven by double-digit growth in biosimilars, both in the fourth quarter and full year, benefitting from recent launches and base-business momentum Operating income of USD 307 million, up by 5% in constant currencies (-18% in USD) Core EBITDA margin[3] in the year of 20.1%, a strong 200 basis-points improvement, reflecting higher biosimilar sales, as well as savings from operational and organizational initiatives Full-year 2025 guidance of mid-single digit net-sales growth[4] and a core EBITDA margin of around 21% Basel, March 5, 2025 – Sandoz (SIX: SDZ / OTCQX: SDZNY), the global leader in generic and biosimilar medicines, announced today results for the full year and net sales for the fourth quarter of 2024.» Mehr auf globenewswire.com

Highlights: Avecho and Sandoz sign an exclusive ten-year development and license agreement ("Agreement") for Avecho's pharmaceutical cannabidiol capsule for insomnia in Australia Avecho to receive upfront, milestone and royalty payments: US$3M (~A$4.8M[1]) in upfront payment US$16M in development milestones prior to commercial sales Tiered royalties ranging from 14% to 19% on net sales Sandoz to purchase the product from Avecho for commercial sale Avecho retains the rights to commercialise the product in all other territories, with Sandoz granted a right of first refusal to exceed any commercial offers Avecho receives Market for over-the-counter cannabidiol registered in Australia forecast to grow to > US$125M per annum[2] CEO Dr Paul Gavin will discuss this announcement further during an investor webinar to be held at 11.00am (AEDT) on Tuesday 4 March 2025 – click here to register MELBOURNE, Australia , March 3, 2025 /PRNewswire/ -- Avecho Biotechnology Limited (ASX: AVE) ("Avecho" or the "Company") today announced it has signed an exclusive ten-year development and licensing agreement with Sandoz Group AG ("Sandoz") for the commercial rights to Avecho's Phase III cannabidiol ("CBD") capsule for insomnia in Australia.  Avecho retains the rights to commercialise the product in all other territories, with Sandoz granted a first right of refusal for these markets.» Mehr auf prnewswire.com